



Case study – Cellomatics BioSciences Ltd

The £20.3m Enabling Innovation programme is one of the largest projects backed by D2N2's European Structural and Investment Funds (ESIF).

The three year programme – to help small and medium-sized enterprises (SMEs) access the expertise of Nottingham Trent, Nottingham and Derby Universities – is half funded by the European Regional Development Fund (ERDF) portion of D2N2's wider ESIF allocation, and half by the universities, which also administer the scheme.

Businesses benefiting have included Cellomatics BioSciences Ltd, based at BioCity Nottingham. The lab-based contract research organisation, provides services to support life science companies with drug development.

It was established in April 2016 by Dr Shailendra Singh, CEO and Founder of Cellomatics Biosciences, after he'd noticed bio-tech and pharmaceutical companies' drive towards outsourcing services to reduce costs.

Dr Singh wanted to expand his company's offer to include lab setup, knowledge and expertise, in-house services, histology (the study of cells) and genotyping (determining the composition of an individual's DNA).

Through Enabling Innovation Cellomatics Biosciences received graduate support from Dr Anushuya Tamang, who joined the company in September 2016, in the field of biological research. Following this initial expansion the company now supports five full-time positions, with the graduate support received via Enabling Innovation making up the core of the Cellomatics lab team.

Cellomatics believes in personalised healthcare. It is performing a study for a genotyping test with clinical specimens originating from India, involving the careful transport of samples some 5,500 miles to Cellomatics; a project led by Dr Tamang.

Dr Singh said: "The support received by the Enabling Innovation programme, both in terms of the part-coverage of salary costs and also the expertise and fresh perspective offered by Dr Tamang, has really helped Cellomatics grow and develop."

"In the past year we have gone from a team of one to a team of five, which has allowed us to greatly improve the level and variety of services we can offer to pharmaceutical companies worldwide."

For more information on Cellomatics BioSciences Ltd see its website at www.cellomaticsbio.com/ and for the Enabling Innovation project see website <https://enablinginnovation.org.uk/>

This project is part-funded by the European Regional Development Fund as part of the European Structural and Investment Funds Growth Programme 2014-2020 in England.